Ratings Omda

Equities

CSAM

NO0010894512

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-07-05 am EDT			5-day change	1st Jan Change
36 ^NOK	0.00%		0.00%	-2.70%

Jun. 05	Omda AS (OB:OMDA) commences an Equity Buyback Plan under the authorization approved on April 25, 2024.	CI
May. 28	Software Group Omda Launches NOK30 Million Share Buyback	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company appears highly valued given the size of its balance sheet.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
OMDA	-2.70%	69.69M		-
VEEVA SYSTEMS INC.	-4.71%	29.66B		C
PRO MEDICUS LIMITED	+36.58%	9.22B		C-
SECTRA AB	+32.70%	4.4B		B-
EVOLENT HEALTH, INC.	-39.45%	2.29B		C-
VERADIGM INC.	-9.44%	1.6B	-	C+
OMNICELL, INC.	-29.39%	1.22B		B
LUNIT INC.	-43.35%	970M		-
SIMULATIONS PLUS, INC.	-13.09%	778M		C
B-SOFT CO.,LTD.	-48.40%	718M		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes